t
Disseminated via PRN on 27 June 2025
27 June 2025
4basebio PLC
("4basebio" or the "Company")
Result of AGM
Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces the result of its Annual General Meeting held earlier today.
The Company decided at the meeting to make certain amendments to Resolutions 14 to 16 which were therefore withdrawn and replacement resolutions will be put forward in due course. All other resolutions were duly passed.
For further enquiries, please contact:
| 4basebio PLC Dr. Heikki Lanckriet, CEO | +44 (0)1223 967 943 |
| Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson / Ed Downes | +44 (0)20 7213 0880 |
| Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes | +44 (0)20 7653 4000 |
| Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks | +44 (0)20 7220 0500 |
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.
